News & Events – Sumitovant

Select Company

January 04, 2021Sumitovant Biopharma Announces the Appointment of Industry Veteran, David Marek, as Chief Executive Officer of Myovant Sciences
December 28, 2020Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
December 23, 2020Sumitovant Biopharma Announces Urovant Sciences Receives U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
December 18, 2020Sumitovant Biopharma Announces Myovant Sciences receives FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
November 12, 2020Sumitovant Biopharma and Urovant Sciences Announce Sumitovant’s Acquisition of Remaining Stake in Urovant
June 22, 2020Sumitovant Biopharma Announces Priority Review and FDA Acceptance of Myovant Sciences New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer
June 19, 2020Sumitovant Biopharma Announces Urovant Sciences Collaboration with Sunovion Pharmaceuticals
June 02, 2020Sumitovant Biopharma Announces Myovant Sciences’ Submission of New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
May 29, 2020Sumitovant Biopharma Announces Myovant Sciences’ Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
May 21, 2020Sumitovant Biopharma’s Family of Companies Achieve Multiple Clinical and Corporate Milestones in the First Full Quarter of Sumitovant’s Operation
1 2 Next »